Vanda reports data from Phase II acute performance anxiety therapy trial

The study assessed the efficacy and safety of VQW-765 in performance anxiety patients.

Innovent begins subject dosing in Phase I study of orismilast

The study will assess orismilast’s safety, tolerability, and pharmacokinetic profile in healthy Chinese participants.

UroGen reports data from Phase IIb trial of bladder cancer treatment

In the trial, UGN-102 offered a median duration of response of 24.4 months in study subjects.

Vaxxinity’s Phase III Covid-19 booster trial meets endpoints

In the trial, the UB-612 vaccine was generally well tolerated, without any serious adverse events occurring.

Catalent expands clinical supply facility in China’s FTZ

The two facilities provide optimised supply solutions to sponsors for clinical trials that are being undertaken in China.